Pfizer Inc. (PFE) Rating Increased to Strong-Buy at Vetr Inc.
Pfizer Inc. (NYSE:PFE) was upgraded by Vetr from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Monday. The firm presently has a $37.42 price objective on the biopharmaceutical company’s stock. Vetr‘s price objective would indicate a potential upside of 15.14% from the stock’s current price.
A number of other research analysts also recently issued reports on the stock. Jefferies Group set a $41.50 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Thursday, July 14th. JPMorgan Chase & Co. set a $40.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, August 3rd. Argus reiterated a “buy” rating and set a $39.00 target price on shares of Pfizer in a research report on Tuesday, October 4th. Credit Suisse Group AG restated an “outperform” rating and set a $40.00 price objective on shares of Pfizer in a report on Monday, August 22nd. Finally, BMO Capital Markets restated a “buy” rating and set a $40.00 price objective on shares of Pfizer in a report on Thursday, July 21st. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $38.63.
Shares of Pfizer (NYSE:PFE) traded down 0.49% on Monday, hitting $32.50. 16,923,468 shares of the stock were exchanged. Pfizer has a 1-year low of $28.25 and a 1-year high of $37.39. The stock has a market cap of $197.13 billion, a price-to-earnings ratio of 28.81 and a beta of 0.86. The stock’s 50-day moving average is $33.95 and its 200-day moving average is $34.35.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/pfizer-inc-pfe-rating-increased-to-strong-buy-at-vetr-inc.html
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The company had revenue of $13.10 billion for the quarter, compared to analyst estimates of $13.01 billion. During the same period in the prior year, the firm posted $0.56 EPS. The company’s quarterly revenue was up 10.9% on a year-over-year basis. Analysts forecast that Pfizer will post $2.46 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be given a dividend of $0.30 per share. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a yield of 3.69%. Pfizer’s dividend payout ratio is presently 95.24%.
A number of institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Pfizer by 1.6% in the second quarter. Vanguard Group Inc. now owns 383,339,513 shares of the biopharmaceutical company’s stock worth $13,497,386,000 after buying an additional 6,193,821 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of Pfizer by 3.2% in the second quarter. BlackRock Fund Advisors now owns 95,416,739 shares of the biopharmaceutical company’s stock worth $3,359,623,000 after buying an additional 2,927,618 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Pfizer by 5.0% in the first quarter. Wellington Management Group LLP now owns 82,813,816 shares of the biopharmaceutical company’s stock worth $2,454,601,000 after buying an additional 3,936,078 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock worth $1,864,446,000 after buying an additional 9,005,107 shares in the last quarter. Finally, BlackRock Group LTD raised its position in shares of Pfizer by 0.9% in the second quarter. BlackRock Group LTD now owns 60,027,464 shares of the biopharmaceutical company’s stock worth $2,113,568,000 after buying an additional 552,493 shares in the last quarter. Hedge funds and other institutional investors own 69.66% of the company’s stock.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.